After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.

The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.

The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.

This week's round-up includes promotions at Astellas, new CSOs at MorphoSys and Tenaya, a new president and CMO at AZTherapies, new directors at BioScience Managers, plus board changes at Intec and Sigilon.